Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Pancreatic Neoplasms 100Carcinoma, Non-Small-Cell Lung 48Neoplasms 34Urinary Bladder Neoplasms 25Lung Neoplasms 25Cholangiocarcinoma 23Breast Neoplasms 22Neoplasm Metastasis 21Ovarian Neoplasms 18Lymphoma, Non-Hodgkin 13Lymphoma 13Recurrence 12Lymphoma, Large B-Cell, Diffuse 11Biliary Tract Neoplasms 11Sarcoma 10Carcinoma, Transitional Cell 9Hodgkin Disease 8Gallbladder Neoplasms 8Fallopian Tube Neoplasms 8Adenocarcinoma 8Bile Duct Neoplasms 7Colorectal Neoplasms 6Triple Negative Breast Neoplasms 5Lymphoma, Follicular 5Liver Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Renal Cell 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4

Interventions

Radiotherapy 11Fluorouracil 8Cisplatin 6Oxaliplatin 5Carboplatin 5Paclitaxel 4Neoadjuvant Therapy 4Leucovorin 4Gefitinib 4pembrolizumab 3Radiation 3Irinotecan 3Taxes 2Surgical Procedures, Operative 2Gemcitabine 2Docetaxel 2Cetuximab 2130-nm albumin-bound paclitaxel 2vandetanib 1spartalizumab 1sargramostim 1romidepsin 1ribociclib 1regorafenib 1oblimersen 1incomplete Freund's adjuvant 1fish oil triglycerides 1dehydroftorafur 1ceritinib 1benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma Of Esophagus × Gemcitabine × Clear all
NCT04683939 2024-10-02

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

BioNTech SE

Phase 1/2 Terminated
13 enrolled 24 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡